Abstract
Background Very low coverage (0.1 to 1x) whole genome sequencing (WGS) has become a promising and affordable approach to discover genomic variants of human populations for Genome-Wide Association Study (GWAS). To support genetic screening using Preimplantation Genetic Testing (PGT) in a large population, the sequencing coverage goes below 0.1x to an ultra-low level. However, its feasibility and effectiveness for GWAS remains undetermined.
Methods We devised a pipeline to process ultra-low coverage WGS data and benchmarked the accuracy of genotype imputation at the combination of different coverages below 0.1x and sample sizes from 2,000 to 16,000, using 17,844 embryo PGT with approximately 0.04x average coverage and the standard Chinese sample HG005 with known genotypes. We then applied the imputed genotypes of 1,744 transferred embryos who have gestational ages and complete follow-up records to GWAS.
Results The accuracy of genotype imputation under ultra-low coverage can be improved by increasing the sample size and applying a set of filters. From 1,744 born embryos, we identified 11 genomic risk loci associated with gestational ages and 166 genes mapped to these loci according to positional, expression quantitative trait locus and chromatin interaction strategies. Among these mapped genes, CRHBP, ICAM1 and OXTR were more frequently reported as preterm birth related. By joint analysis of gene expression data from previous studies, we constructed interrelationships of mainly CRHBP, ICAM1, PLAGL1, DNMT1, CNTLN, DKK1 and EGR2 with preterm birth, infant disease and breast cancer.
Conclusions This study not only demonstrates that ultra-low coverage WGS could achieve relatively high accuracy of adequate genotype imputation and is capable of GWAS, but also provides insights into uncovering genetic associations of gestational age trait existed in the fetal embryo samples from Chinese or Eastern Asian populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the Early Career Schema (27204518) of the Hong Kong Research Grants Council for RL, partially by General Research Funding of Hong Kong Research Grants Council (17113721) for RL and (17117918) for BY, by the University Grants Committees Fund from the University of Hong Kong for RL, partially by National Key Research and Developmental Program of China (2018YFC1004900) for YT, by the Innovation and Technology Fund (ITF/331/17FP) of Innovation and Technology Commission of the Hong Kong SAR government for TL.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All individual samples in the technical concordance cohort and clinical cohort, and protocols used in this study have been reviewed and approved by the Institutional Review Board (IRB) of China International Trust Investment Corporation - Xianngya (IRB Reference No. LL-SC-2020-004). The need to obtain informed consent has been waived by the IRB due to the study's retrospective nature. Following the regulations of the Human Genetic Resources Administration of China, all genetic materials involved in this study have been reviewed and approved by Ministry of Science and Technology of the People's Republic of China (Approval No. [2022] GH1831). The experimental methods were in accordance with the principles of the Helsinki Declaration.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets supporting the conclusions of this article are included within the article and its additional files. The significant SNPs and candidate SNPs are listed in Additional file 1: Tables S3 and S4, respectively. The processed or raw counts of mRNA expression datasets shown in Additional file 1: Table S8 was downloaded from Gene Expression Omnibus (GEO)/National Center for Biotechnology Information (NCBI).
Abbreviations
- WGS
- whole genome sequencing
- NGS
- next-generation sequencing
- GWAS
- genome-wide association study
- bp
- base pair
- SNP
- single nucleotide polymorphism
- PTB
- preterm birth
- PGT
- preimplantation genetic testing
- MAF
- minor allele frequency
- LD
- linkage disequilibrium
- HWE
- Hardy-Weinberg equilibrium
- WGA
- whole genome amplification
- PCA
- principal component analysis
- eQTL
- expression quantitative trait locus
- FDR
- false discovery rate
- GO
- gene ontology
- BPD
- bronchopulmonary dysplasia
- ER
- Estrogen receptor
- PR
- Progesterone receptor
- HER2
- human epidermal growth factor receptor 2
- TNBC
- Triple-negative breast cancer
- DEG
- differentially expressed gene
- AF
- allele frequency
- GIAB
- Genome in a Bottle
- BWA
- Burrows-Wheeler Aligner
- GEO
- Gene Expression Omnibus
- NCBI
- National Center for Biotechnology Information
